Connor MP, Barsouk A, Elghawy O, Lai C Advancements in targeted therapies for acute myeloid leukemia , Curr Opin Pharmacol, 87: 2026

Kopmar NE, Gooley TA, Roloff GW, Zhang A, Aldoss I, Lin C, Bezerra E, Muhsen I, Jeyakumar N, Dykes KC, O'Connor T, Tang K, Chen EC, Connor M, Frey NV, Gordillo CA, Hilal T, Al Darobi AH, Hoeg RT, Irizarry Gatell VM, Valtis YK, Jackson CW, Kota VK, Koura D, Boccucci J, Guzowski C, Kumaran MV, Ladha A, Lee CJ, Majhail NS, Malik SA, Mathews J, Miller K, Moore J, Mountjoy L, O'Dwyer KM, Odstrcil Bobillo S, Oliai CH, Oluwole OO, Pradeep R, Othman T, Ramakrishnan A, Reshef R, Sasine J, Vasu S, Schwartz M, Shaughnessy P, Stefan M, Stock W, Sutherland KC, Tan V, Solh MM, Tracy S, Luskin M, Logan AC, Leonard JT, Hill L, Tsai SB, Advani AS, Ulrickson M, Bachanova V, Dholaria B, Park JH, Battiwalla M, Faramand R, Shah BD, Yaghmour G, Muffly LS, Cassaday RD Toxicity of Brexucabtagene Autoleucel as a Standard Therapy for Adults with Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia , Blood Immunol Cell Ther: 2025

Logan A, Yalniz F, Zhang A, Miller K, Sutherland K, Jeyakumar N, Srinagesh H, Grunwald M, Kota V, Boccucci J, Ulrickson M, Al-Darobi A, Sasine J, Hill L, Muhsen I, Advani A, Aldoss I, Othman T, Sandhu K, Reshef R, , Luskin M, Chen E, Lin C, Cassaday R, Kopmar N, Solh M, Lee C, Odstrcil Bobillo S, Tsai S, O'Connor T, Hilal T, Park J, Valtis Y, Vasu S, Bezerra E, Wang E, Leonard J, Tan V, O'Dwyer K, Moore J, McCauley R, Majhail N, Mountjoy L, Ramakrishnan A, Malik S, Battiwalla M, Shaughnessy P, Mathews J, Jamy O, Mohty R, Kumaran M, Hoeg R, Stock W, Roloff G, Oliai C, Lill G, Schwartz M, Koura D, Dykes K, Daunov M, Byrd K, Bachanova V, Tracy S, Grover P, Frey N, Connor M, Yaghmour G, Irizarry Gatell V, Jackson C, Oluwole O, Dholaria B, Faramand R, Muffly L Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world , Blood, 146(Supplement 1): 2025,516

Connor M, Hwang W, Gill S, Perl A, Jordan Bruno X, Hossain N, Lai C, Loren A, Luger S, Matthews A, McCurdy S, Munshi P, Pratz K, Cervini A, McConville J, Shea J, Tongue C, Difilippo H, Kesselman J, Marshall A, Four M, Christensen S, Gonzalez V, Jadlowsky J, Plesa G, Siegel D, Leskowitz R, Fraietta J, Levine B, Porter D, Hexner E, June C, Svoboda J, Frey N IL18-armored CAR T cells in relapsed/refractory B cell acute lymphoblastic leukemia , Blood, 146(Supplement 1): 2025,812

McCauley R, Zhang A, Kota V, Boccucci J, Grunwald M, Ulrickson M, Hill L, Muhsen I, Sasine J, Advani A, Aldoss I, Sandhu K, Reshef R, Luskin M, Lin C, Cassaday R, Kopmar N, Solh M, Odstrcil Bobillo S, Tsai S, Hilal T, Shah B, Faramand R, Park J, Valtis Y, Othman T, Vasu S, Bezerra E, Leonard J, Tan V, O'Dwyer K, Moore J, Jamy O, Mohty R, Kumaran M, Hoeg R, Stock W, Oliai C, Lill G, Schwartz M, Koura D, Dykes K, Logan A, Daunov M, Byrd K, Yalniz F, Frey N, Connor M, Yaghmour G, Irizarry Gatell V, Jackson C, Oluwole O, Al-Darobi A, Chen E, Lee C, O'Connor T, Dholaria B, Bachanova V, Tracy S, Srinagesh H, Miller K, Sutherland K, Majhail N, Mountjoy L, Malik S, Ramakrishnan A, Shaughnessy P, Mathews J, Wang E, Battiwalla M, Roloff G, Muffly L CRS/ICANS Prophylaxis does not Improve Outcomes in adult patients with Relapsed/Refractory B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel , Blood, 146(Supplement 1): 2025,2396

Leonard J, Ladha A, Faramand R, Roloff G, Valtis Y, Tan V, Miller K, Zhang A, Grunwald M, Kota V, Boccucci J, Ulrickson M, Al-Darobi A, Hill L, Muhsen I, Sasine J, Advani A, Sandhu K, Reshef R, Luskin M, Chen E, Lin C, Cassaday R, Kopmar N, Solh M, Lee C, Odstrcil Bobillo S, Tsai S, O'Connor T, Hilal T, Park J, Vasu S, Bezerra E, O'Dwyer K, Moore J, Wang E, McCauley R, Majhail N, Ramakrishnan A, Mountjoy L, Malik S, Battiwalla M, Shaughnessy P, Mathews J, Srinagesh H, Sutherland K, Jamy O, Mohty R, Kumaran M, Hoeg R, Oliai C, Lill G, Stock W, Schwartz M, Othman T, Koura D, Dykes K, Logan A, Daunov M, Byrd K, Yalniz F, Bachanova V, Tracy S, Grover P, Connor M, Yaghmour G, Irizarry Gatell V, Jackson C, Oluwole O, Dholaria B, Frey N, Muffly L, Shah B, Aldoss, I KMT2Ar, but not other high-risk genetics, adversely impacts outcomes in adult patients with relapsed/refractory (R/R) Philadelphia chromosome negative B-cell acute lymphoblastic leukemia (B-ALL) treated with brexucabtagene autoleucel (Brexu-cel) , Blood, 146(Supplement 1): 2025,3365

Svoboda J, Schuster S, Porter D, Cook M, Nasta SD, Landsburg D, Barta S, Ruella M, Chong E, Carter J, Thomas C, Tomasulo E, Frey N, Connor M, Shea J, Cervini A, McConville J, Tongue C, Four M, Marshall A, Hwang W, Leskowitz R, Gonzalez V, Christensen S, Plesa G, Siegel D, Jadlowsky J, Fraietta J, Levine B, Hexner E, June C IL18-armored CAR T cells in patients with CLL/SLL and Richter's transformation after prior BTK inhibitor and venetoclax failure , Blood, 146(Supplement 1): 2025,2394

Valtis Y, Sandhu K, Faramand R, Zhang A, Miller K, Hill L, Muhsen I, Othman T, Luskin M, Chen E, Oliai C, Lill G, Cassaday R, Kopmar N, Logan A, Connor M, Hilal T, Park J, Solh M, Guzowski C, Leonard J, Tan V, Jeyakumar N, Srinagesh H, Kumaran M, Hoeg R, Koura D, Dykes K, Stock W, Irizarry Gatell V, Jackson C, Oluwole O, Dholaria B, O'Dwyer K, Moore J, Ulrickson M, Al-Darobi A, Byrd K, Tsai S, O'Connor T, Wang E, McCauley R, Jamy O, Mohty R, Roloff G, Sutherland K, Aldoss I, Shah B, Muffly L, Frey N Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis , Blood, 146(Supplement 1): 2025,2715

Valtis YK, Lin C, Nemirovsky D, Devlin S, Rejeski K, Curran KJ, Wang X, Shah NN, Jeyakumar N, Miller K, Zhang A, Kota VK, Al Darobi AH, Muhsen I, Sasine J, Aldoss I, Advani AS, Reshef R, Chen EC, Kopmar N, Tsai SB, Hilal T, Shah BD, Faramand R, Solh MM, Tan V, Bezerra E, Battiwalla M, Ramakrishnan A, Mathews J, Shaughnessy P, Mountjoy L, Hoeg RT, Dykes KC, Logan AC, Kumaran MV, Schwartz M, Tracy S, Moore J, Bobillo SO, Frey NV, Connor M, Ladha A, Dholaria B, Sutherland K, Roloff GW, Muffly LS, Park JH, Nair M, Ulrickson M, Ahmed M, Othman T, Bacani S, Stefan M, Luskin M, Cassaday R, O'Connor T, Guzowski C, Gordillo L, Vasu S, Majhail N, Malik S, Oliai C, Koura D, Stock W, Bachanova V, O'Dwyer K, Lee C, Yaghmour G, Oluwole O CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia , Blood Adv, In Press: 2025

O'Connor TE, Lin C, Roloff GW, Zhang A, Miller K, Aldoss I, Kopmar NE, Dekker SE, Gupta VK, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Sutherland K, Dykes KC, Ahmed M, Chen E, Zambrano H, Bradshaw D, Mercadal S, Schwartz M, Tracy S, Connor MP, Kubiak M, Mukherjee A, Majhail N, Battiwalla M, Mountjoy L, Malik SA, Mathews J, Shaughnessy P, Blunk B, Logan AC, Ladha A, Advani AS, Stefan M, Guzowski C, Hoeg RT, Hilal T, Moore J, O'Dwyer KM, Hill LC, Sasine J, Oliai C, Solh MM, Lee CJ, Kota VK, Koura D, Kumaran MV, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Bishop MR, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly LS, Tsai SB, Dholaria B The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia , Bone Marrow Transplant, Online ahead of print: 2025